Skip to main content

Loading market data...

GMAB

Genmab A/S

NASDAQ • United states

$39.07

+$0.57

(+1.48%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Catalyst Evidence

No verified catalyst stored yet

Click “View” to see the stored chain of evidence (if available).

Management
Credibility
Score

Genmab A/S (GMAB)

Unavailable

Quotes may be delayed

$24.38B

Market Cap

3,777,521

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

Genmab A/S Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: TOLDBODGADE 33, 1253 COPENHAGEN K, G7
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

6 Oct 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Genmab A/S.

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Genmab A/S.

15 May 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Genmab A/S.

17 Feb 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in Genmab A/S.

17 Feb 2026

Genmab A/S securities registration filing

Genmab A/S filed a registration or prospectus document concerning securities.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Verified Capital Structure Unavailable

Balance-sheet, credit-rating, debt, and capital-activity data require sourced financial statement ingestion.

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Verified Financial Statements Unavailable

Verified financial statement data is not ingested for this stock yet.

Analyst Consensus

Buy

Target: $99.70

155.2% upside potential

📈

Strong Buy

Unavailable

👍

Buy

9

⏸️

Hold

1

📉

Sell

0

10 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 10:48 UTC Targets range 42.00–360.18 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

29

Dec 2025

GENMAB A/S

Open-market purchase

$97.00 per share

76,920,005 shares

26

Dec 2025

GENMAB A/S

Open-market purchase

$97.00 per share

2,978 shares

26

Dec 2025

GENMAB A/S

Open-market purchase

$97.00 per share

142,610 shares

24

Dec 2025

GENMAB A/S

Open-market purchase

$97.00 per share

96,082 shares

23

Dec 2025

GENMAB A/S

Open-market purchase

$97.00 per share

561,042 shares

22

Dec 2025

GENMAB A/S

Open-market purchase

$97.00 per share

15,710 shares

19

Dec 2025

GENMAB A/S

Open-market purchase

$97.00 per share

66,264 shares

18

Dec 2025

GENMAB A/S

Open-market purchase

$97.00 per share

212,177 shares

17

Dec 2025

GENMAB A/S

Open-market purchase

$97.00 per share

150,795 shares

16

Dec 2025

GENMAB A/S

Open-market purchase

$97.00 per share

120,752 shares

Top Shareholders

Paradigm Biocapital Advisors Lp

13,133,131 shares

64.827% change

6/30/2026

Orbis Allan Gray Ltd

11,368,161 shares

-12.049% change

6/30/2026

Alliancebernstein L.P.

8,644,877 shares

-9.545% change

6/30/2026

Deerfield Management Company, L.P.

6,865,000 shares

178.838% change

6/30/2026

Deep Track Capital, Lp

5,650,000 shares

54.235% change

6/30/2026

Arrowstreet Capital, Limited Partnership

4,975,324 shares

0% change

6/30/2026

Blackrock, Inc.

4,671,252 shares

2.969% change

6/30/2026

Sofinnova Investments, Inc.

4,045,215 shares

437.741% change

6/30/2026

Renaissance Technologies Llc

3,517,850 shares

-20.312% change

6/30/2026

Two Sigma Investments, Lp

3,506,843 shares

49.901% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 10:49 UTC· 21 hours ago

Research coverage and investment tools

Genmab A/S (GMAB) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Pharmaceutical Preparations). Its last price was US$39.07 on 20 Oct 2026. That is 93% of the way from its 52-week low of US$23.62 to its 52-week high of US$40.17. Its market capitalisation was US$24.38 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

SCHEDULE 13G · 6 Oct 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Genmab A/S.
SCHEDULE 13G/A · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Genmab A/S.
SCHEDULE 13G/A · 15 May 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Genmab A/S.
SCHEDULE 13G/A · 17 Feb 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in Genmab A/S.
S-8 · 17 Feb 2026

Genmab A/S securities registration filing (opens in a new tab)

Genmab A/S filed a registration or prospectus document concerning securities.

Insider	Date	Transaction	Shares	Average price	Filing
GENMAB A/S	29 Dec 2025	Open-market purchase (P)	+76,920,005	$97.00	Form 4 (opens in a new tab)
GENMAB A/S	26 Dec 2025	Open-market purchase (P)	+2,978	$97.00	Form 4 (opens in a new tab)
GENMAB A/S	26 Dec 2025	Open-market purchase (P)	+142,610	$97.00	Form 4 (opens in a new tab)
GENMAB A/S	24 Dec 2025	Open-market purchase (P)	+96,082	$97.00	Form 4 (opens in a new tab)
GENMAB A/S	23 Dec 2025	Open-market purchase (P)	+561,042	$97.00	Form 4 (opens in a new tab)
GENMAB A/S	22 Dec 2025	Open-market purchase (P)	+15,710	$97.00	Form 4 (opens in a new tab)
GENMAB A/S	19 Dec 2025	Open-market purchase (P)	+66,264	$97.00	Form 4 (opens in a new tab)
GENMAB A/S	18 Dec 2025	Open-market purchase (P)	+212,177	$97.00	Form 4 (opens in a new tab)
GENMAB A/S	17 Dec 2025	Open-market purchase (P)	+150,795	$97.00	Form 4 (opens in a new tab)
GENMAB A/S	16 Dec 2025	Open-market purchase (P)	+120,752	$97.00	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Paradigm Biocapital Advisors Lp	6/30/2026	13,133,131	64.827%
Orbis Allan Gray Ltd	6/30/2026	11,368,161	-12.049%
Alliancebernstein L.P.	6/30/2026	8,644,877	-9.545%
Deerfield Management Company, L.P.	6/30/2026	6,865,000	178.838%
Deep Track Capital, Lp	6/30/2026	5,650,000	54.235%
Arrowstreet Capital, Limited Partnership	6/30/2026	4,975,324	0%
Blackrock, Inc.	6/30/2026	4,671,252	2.969%
Sofinnova Investments, Inc.	6/30/2026	4,045,215	437.741%
Renaissance Technologies Llc	6/30/2026	3,517,850	-20.312%
Two Sigma Investments, Lp	6/30/2026	3,506,843	49.901%

Previous close: 38.50 USD
Day range: 38.42 – 39.41 USD
52-week range: 23.62 – 40.17 USD
Volume: 3,777,521
Market cap: $24.38B
Average volume: 3,117,450
Shares outstanding: 624.06M
Beta (5Y monthly): 0.81

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 08:06 UTC· 36 minutes ago

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for GMAB yet

Financial statements
Balance sheet
Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.